Busca avançada
Ano de início
Entree
(Referência obtida automaticamente do Web of Science, por meio da informação sobre o financiamento pela FAPESP e o número do processo correspondente, incluída na publicação pelos autores.)

Employing proteomics to unravel the molecular effects of antipsychotics and their role in schizophrenia

Texto completo
Autor(es):
Cassoli, Juliana S. [1] ; Guest, Paul C. [1] ; Santana, Aline G. [1] ; Martins-de-Souza, Daniel [2, 1]
Número total de Autores: 4
Afiliação do(s) autor(es):
[1] Univ Campinas UNICAMP, Inst Biol, Dept Biochem & Tissue Biol, Lab Neuroprote, Campinas, SP - Brazil
[2] Univ Estadual Campinas, Neurobiol Ctr, Campinas, SP - Brazil
Número total de Afiliações: 2
Tipo de documento: Artigo de Revisão
Fonte: PROTEOMICS CLINICAL APPLICATIONS; v. 10, n. 4, SI, p. 442-455, APR 2016.
Citações Web of Science: 4
Resumo

Schizophrenia is an incurable neuropsychiatric disorder managed mostly by treatment of the patients with antipsychotics. However, the efficacy of these drugs has remained only low to moderate despite intensive research efforts since the early 1950s when chlorpromazine, the first antipsychotic, was synthesized. In addition, antipsychotic treatment can produce often undesired severe side effects in the patients and addressing these remains a large unmet clinical need. One of the reasons for the low effectiveness of these drugs is the limited knowledge about the molecular mechanisms of schizophrenia, which impairs the development of new and more effective treatments. Recently, proteomic studies of clinical and preclinical samples have identified changes in the levels of specific proteins in response to antipsychotic treatment, which have converged on molecular pathways such as cell communication and signaling, inflammation and cellular growth, and maintenance. The findings of these studies are summarized and discussed in this review and we suggest that this provides validation of proteomics as a useful tool for mining drug mechanisms of action and potentially for pinpointing novel molecular targets that may enable development of more effective medications. (AU)

Processo FAPESP: 14/14881-1 - Compreensão da influência de componentes da via glicolítica na função dos oligodendrócitos: uma relação com os achados em esquizofrenia
Beneficiário:Juliana Silva Cassoli
Linha de fomento: Bolsas no Brasil - Pós-Doutorado
Processo FAPESP: 13/08711-3 - Desenvolvimento de um teste preditivo para medicação bem sucedida e compreensão das bases moleculares da esquizofrenia através da proteômica
Beneficiário:Daniel Martins-de-Souza
Linha de fomento: Auxílio à Pesquisa - Apoio a Jovens Pesquisadores